The public offering subscription for Ingenia Therapeutics concluded around 4 p.m. on the 31st. A total of 20,435 subscriptions were received during the two-day period from the 30th to the 31st, with Samsung Securities as the lead underwriter.

Equal Allocation 30.58 Shares · Proportional Competition Ratio 5.16:1

According to the subscription results, the number of equally allocated shares based on the minimum subscription requirement was tallied at 30.58 shares. The proportional competition ratio recorded 5.16 to 1. Earlier, the institutional investor demand forecasting showed a competition ratio of 50.4 to 1.

With the somewhat lackluster demand forecasting competition ratio and the equal allocation shares remaining at around the 30-share level, attention is now focused on the market response on the listing date of the 18th. In particular, the recent highly volatile market trends must also be taken into consideration.

Ingenia Therapeutics, Which Possesses 'LCIDEC' and 'TIE body' Platform Technologies

Ingenia Therapeutics has independently developed the 'LCIDEC' platform technology and 'TIE body' technology. According to the company, the main target diseases include ocular retinal diseases, glaucoma, chronic kidney disease, cardiovascular diseases such as myocardial infarction, artery-related diseases such as atherosclerosis, and brain diseases such as stroke and dementia.

[This article was written for informational purposes only and does not constitute an investment solicitation or a buy/sell recommendation for any specific stock. The final decision and responsibility for investments lie with the investor.]